the article says this is perplexing, "suspicious," and perhaps based on "hope," since there is no new news: http://www.smallcapnetwork.com/Real...CBAI-HEB/s/via/10/article/view/p/mid/3/id/18/ I wonder if it has to do with investors reading the MLV abstracts from the International Human Retrovirus conference and realizing that retroviral causation could actually be a factor? I don't doubt that ampligen can help some deserving patients who need options, but I wonder if HEB can pull off readying a medication. More investors could help! Odd that the article says ampligen is for "chronic fatigue syndrome (CFS)", when Hemispherx says it's for important neuro-immune diseases. The article could at least use ME/CFS and spell out Myalgic Encephalomyelitis even if it didn't want to use space explaining what disease this is.